**Aclarion, Inc. Reports Fiscal Year 2025 Results**
Aclarion, Inc., a healthcare technology company focused on improving clinical treatments through Magnetic Resonance Spectroscopy (MRS), announced its financial results for the fiscal year ended December 31, 2025. The company reported total revenue of $75,730, an increase of $30,006, or 65.6%, compared to $45,724 in 2024. Cost of revenue decreased by $15,756, or 18.6%, to $68,902, compared to $84,658 in the previous year. The company's gross profit was $6,828, a significant improvement from a gross loss of $38,934 in the prior year.
Operating expenses for 2025 totaled $7.06 million, an increase of $1.59 million, or 29%, compared to $5.47 million in 2024. Sales and marketing expenses increased by $924,044, or 94.6%, to $1.90 million, driven by higher post-clearance clinical services related to the CLARITY Trial and increased product marketing consulting. Research and development expenses rose by $145,023, or 16.3%, to $1.03 million, primarily due to higher patent maintenance fees and bonus expenses. General and administrative expenses increased by $516,039, or 14.3%, to $4.12 million, mainly due to higher accruals under the company’s incentive bonus program and increased insurance expenses. The company's loss from operations was $7.05 million, compared to $5.51 million in the previous year.
Other expenses for the year included a gain on extinguishment of debt of $73,272, a change in fair value of warrant and derivative liabilities of $11,806, penalties and settlements of $672,625, and interest income of $411,061. The company reported a net loss of $7.23 million, compared to a net loss of $6.99 million in 2024. Net loss per share allocable to common stockholders was $13.61, based on a weighted average of 532,036 shares outstanding. As of December 31, 2025, Aclarion had cash and cash equivalents of $12.04 million.
Aclarion is focused on securing payer contracts for its Category III CPT codes and converting them to Category I codes. The company is also prioritizing key markets and expanding its commercial operations in the United States and the United Kingdom. Subsequent to the fiscal year end, Aclarion completed a registered direct public offering in January 2026, raising approximately $10.4 million before deducting fees and expenses. The company believes its current cash resources will be sufficient to fund operations into the first quarter of 2028.
About Aclarion, Inc.
Aclarion, Inc. develops non-invasive diagnostic technology using Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to identify painful intervertebral discs causing chronic low back and neck pain. Its flagship product, NOCISCAN®, enhances standard MRI scans by chemically analyzing disc tissue to guide treatment decisions, primarily for spine surgeons and imaging centers. The company’s software-driven platform aims to improve patient outcomes and reduce healthcare costs in the large, costly back pain market.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.